Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03613727 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03613727 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 61 participants.
The verdict
NCT03613727, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
Interventions
- DRUG Intravenous (IV) and oral Vitamin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03613727
The ClinicalTrials.gov registry entry for NCT03613727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous (IV) and oral Vitamin C is the first listed.
NCT03613727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03613727 about?
NCT03613727 is a clinical study titled "Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients". This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
What is the current status of trial NCT03613727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-10-01. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT03613727?
The interventions under investigation include: Intravenous (IV) and oral Vitamin C (DRUG).
Who is sponsoring clinical trial NCT03613727?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.